Compare Cronos Group Inc (CRON) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs 22nd Century Group Inc — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: Cronos Group Inc is far larger — about 1898.1× 22nd Century Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and 22nd Century Group Inc for 32 Days on average.
| CRON | XXII | |
|---|---|---|
Market Cap | $1.18B | $621.67K |
Volume | 968,037 | 45,625 |
Sector | Health | Consumer Staples |
52-Week High | $3.55 | $483.00 |
52-Week Low | $2.30 | $0.80 |
Typical Hold Time | 22 Days | 32 Days |
Enterprise Value | $387.62M | -$3.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 0.62% on the day, with a bearish technical signal and neutral oscillators. Revenue grew to $146.59M in 2025, but net income was -$9.45M. Recent Q2 2026 earnings beat expectations with EPS of $0.09. The company held its first Investor Day in September 2026, highlighting international expansion and cash flow focus.
Outlook is mixed: strong revenue growth and a solid balance sheet with no debt support upside, but profitability remains inconsistent. Risks include cash flow volatility and competitive pressures. Analyst consensus is cautious with 60% hold ratings, reflecting uncertainty amid expansion efforts.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
